Posted by Michael Wonder on 16 Feb 2024
FDA approves osimertinib with chemotherapy for EGFR mutated non-small-cell lung cancer
16 February 2024 - Today, the FDA approved osimertinib (Tagrisso, AstraZeneca) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA approved test.
Efficacy was evaluated in FLAURA 2, an open-label, randomised trial of 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation positive locally advanced or metastatic non-small cell lung cancer and no prior systemic therapy for advanced disease.
